YOU ARE NOW CONNECTED TO THE TOXLINE (1981 FORWARD, NON-ROYALTY) FILE. ==CHORIORETINOPATHY, SEROUS== 2 AUTHOR Quillen DA AUTHOR Gass DM AUTHOR Brod RD AUTHOR Gardner TW AUTHOR Blankenship GW AUTHOR Gottlieb JL TITLE Central serous chorioretinopathy in women. SOURCE Ophthalmology; VOL 103, ISS 1, 1996, P72-9 ABSTRACT BACKGROUND: Central serous chorioretinopathy is a disorder that typically affects young and middle-aged men. Although extensive information is available pertaining to the clinical features of central serous chorioretinopathy in men, little is known about this condition in women. MATERIALS AND METHODS: The authors reviewed the medical records and photographic files of women who received a diagnosis of central serous chorioretinopathy. The women were divided into three groups for data analysis: idiopathic, exogenous corticosteroid use, and pregnancy. RESULTS: Fifty-one women with active central serous chorioretinopathy were evaluated. These findings in women with idiopathic serous chorioretinopathy were similar to those described in men, with the exception that women tend to be older at the time of onset. Central serous chorioretinopathy in women taking exogenous corticosteroids more likely was characterized by bilateral involvement and subretinal fibrin. Central serous chorioretinopathy in pregnant women typically developed in the third trimester and resolved spontaneously within 1-2 months after delivery. CONCLUSION: Idiopathic central serous chorioretinopathy is similar in women and men, with the exception that women tend to be more older at the time of onset. The finding of exogenous corticosteroid use in a significant number of women in our study provides further support that cortisol may play a role in the development of central serous chorioretinopathy. The mechanism by which cortisol influences the development of central serous chorioretinopathy is unclear. 24 AUTHOR Gaub J AUTHOR Poulsen AG AUTHOR Pedersen C AUTHOR Tinning S AUTHOR Hojgaard K AUTHOR Thomson MH AUTHOR Faber V AUTHOR Nielsen JO TITLE Efficacy and safety of two different dose levels of ganciclovir for the treatment of cytomegalovirus chorioretinitis in AIDS patients. SOURCE Scand J Infect Dis; VOL 20, ISS 5, 1988, P479-82 ABSTRACT The effect of different dosages of ganciclovir on proved cytomegalovirus chorioretinitis was tested in a randomized trial on 11 homosexual men with AIDS. The effect of 5 mg/kg/day was as good as 10 mg/kg/day. The lower dosage had less toxicity. 15 AUTHOR Browning DJ TITLE Nadolol in the treatment of central serous retinopathy [letter] SOURCE Am J Ophthalmol; VOL 116, ISS 6, 1993, P770-1 26 AUTHOR Gross M AUTHOR Froom P AUTHOR Tendler Y AUTHOR Mishori M AUTHOR Ribak J TITLE Central Serous Retinopathy (Choroidopathy) In Pilots SOURCE Aviation, Space, and Environmental Medicine, Vol. 57, No. 5, pages 457-458, 5 references, 19861986 ABSTRACT The occurrence of central serous retinopathy was studied among pilots in Israel. The predictive value of impaired visual acuity during the initial attack for recurrences was studied. Clinical charts of pilots were reviewed for central serous retinopathy and reduction in visual acuity during the initial attack. Fourteen pilots had a total of 26 attacks of central serous retinopathy. Visual acuity decreased during the attack in 12 of the 14 and returned to normal in all but 3. The incidence of serous retinopathy was 1.3 per 1,000 pilots per year. The average time to return to duty was 4.8 months. Of the six pilots with recurrent attacks, five had a decrease in acuity during the initial attack to at least 20/30 in the affected eye. In those whose visual acuity did not decrease below 20/25, only one of seven had recurrent attacks. The rate of recurrence was 42.9 percent. The authors conclude that there is no evidence that the incidence of central serous retinopathy differs in pilots from the general population. Additional studies will be needed to determine if flying predisposes toward central serous retinopathy. The severity of the decrease in visual acuity during the initial attack can be used to predict those who will develop recurrences. YOU ARE NOW CONNECTED TO THE TOXLINE65 (1965 - 80, NON-ROYALTY) FILE. 1 AUTHOR Landers MB 3d AUTHOR Shaw HE Jr AUTHOR Anderson WB Jr AUTHOR Sinyai AJ TITLE Argon laser treatment of central serous chorioretinopathy. SOURCE Ann Ophthalmol; VOL 9, ISS 12, 1977, P1567-72 ABSTRACT Thirty patients (33 eyes) with central serous chorioretinopathy were treated with argon laser photocoagulation. Visual acuity improved in 28 eyes (85%) and remained the same in 5 (15%). In all cases symptomatic improvement occurred and final visual acuity was 20/30 or better. No complications resulted from treatment. In deciding when to treat, one must consider the duration of a given episode, degree of visual impairment, visual needs of the patient, and location of the leakage site. While argon laser therapy of central serous chorioretinopathy is effective and safe, inadvertent foveal photocoagulation and intraretinal macular absorption of argon laser energy are potential therapeutic hazards. YOU ARE NOW CONNECTED TO THE MEDLINE (1994 - 97) FILE. 2 AUTHOR Spaide RF AUTHOR Campeas L AUTHOR Haas A AUTHOR Yannuzzi LA AUTHOR Fisher YL AUTHOR Guyer DR AUTHOR Slakter JS AUTHOR Sorenson JA AUTHOR Orlock DA TITLE Central serous chorioretinopathy in younger and older adults. SOURCE Ophthalmology 1996 Dec;103(12):2070-9; discussion 2079-80 ABSTRACT PURPOSE: The purpose of the study is to investigate the demographic characteristics and clinical findings of central serous chorioretinopathy (CSC). METHODS: This study examined a consecutive series of 130 patients with CSC seen over an 18-month period. RESULTS: The mean age of the patients when examined was 51 years, and the male-to-female ratio was 2.6:1.0. A total of 62 patients were older than 50 years of age when first examined. Although the patients shared some clinical and angiographic similarities, the older patients had a lower mean visual acuity and were more likely to have diffuse retinal pigment epitheliopathy, bilateral involvement, and secondary choroidal neovascularization than were the younger patients. With ophthalmoscopic and angiographic examination results, it was possible to differentiate CSC in older adults from choroidal neovascularization. CONCLUSION: This study expands the clinical concept of CSC. The male-to-female ratio was much lower, and the range of ages of the patients was much greater than in previous studies. Disease manifestations in older adults differed somewhat from those seen in younger adults. In older patients, CSC can be distinguished from other exudative maculopathies, particularly that of choroidal neovascularization secondary to age-related macular degeneration. 11 AUTHOR Khairallah M AUTHOR Nouira F AUTHOR Gharsallah R AUTHOR Chachia N TITLE [Central serous chorioretinopathy in a pregnant woman] SOURCE J Fr Ophtalmol 1996;19(3):216-21 ABSTRACT PURPOSE: A case of central serous chorioretinopathy in a 28-year-old pregnant woman is reported. METHODS: A complete ocular examination was performed including fundus biomicrospic examination and fluorescein angiography. RESULTS: Examination of the left eye revealed central serous chorioretinopathy associated with greyish-white subretinal exudate. In the right eye, sequaele of asymptomatic central serous chorioretinopathy was found. Reattachment of the retina and dissolution of the exudate, with return of visual acuity to normal, occurred soon after delivery. CONCLUSION: This case report is the 19th case of central serous chorioretinopathy during pregnancy reported to date. Central serous chorioretinopathy in pregnant woman is often associated with subretinal exudation which is probably fibrinous in nature. The affection resolves spontaneously at the end of pregnancy or after delivery, but may recur in the context or outside of subsequent pregnancy. The special conditions of pregnancy, including haemodynamic, biological and psychological alterations may lead susceptible women to develop central serous chorioretinopathy. 12 AUTHOR Makabe R AUTHOR Gumbel H TITLE [Central serous chorioretinitis. Therapy experience over 20 years with and without laser coagulation] SOURCE Ophthalmologe 1995 Oct;92(5):654-6 ABSTRACT Since 1969, 1,179 eyes with central serous chorioretinopathy have been examined with fluorescein fundus angiography. The classic form with fluorescein leakage (type I) decreased in incidence from 86.4% to 55.4%, while an atypical form with frequent serous pigment epithelial detachment (type II) increased from 12.6% to 33.0%, and the mixed form (type I + II) increased from 1 to 11.6%. In type I with delayed healing laser coagulation of the leakage was performed, which improved the visual acuity from 0.64 to 0.92 an average (n = 122), while in cases without laser coagulation the percentage improved only from 0.66 to 0.84 on average (n = 34) with a statistically significant difference (t = 2.64, P < 0.01). Laser coagulation was especially beneficial in the mixed form (n = 16), in which the visual acuity improved from 0.42 to 0.86 on average. The proportion of women increased from 10.7 to 17.9%. The patient age tended to be higher in women more than in men. 13 AUTHOR Yap EY AUTHOR Robertson DM TITLE The long-term outcome of central serous chorioretinopathy. SOURCE Arch Ophthalmol 1996 Jun;114(6):689-92 ABSTRACT OBJECTIVE: To assess the long-term outcome of central serous chorioretinopathy (CSR) among a group of patients who previously participated in a prospective argon laser photocoagulation study of CSR. DESIGN: Thirty-eight of 41 surviving patients with CSR participating in an earlier study were invited to participate in a follow-up study that included history taking, ophthalmoscopy, biomicroscopy, and fundus photography. RESULTS: Thirty-seven (38 eyes) of 38 surviving patients (97%) were available for follow-up between 11 and 15 years after participation in the earlier study. There were no clinically documented or historical recurrences of CSR among the six eyes previously treated by direct laser photocoagulation. There were 13 clinically documented recurrences and four historical recurrences among the 32 eyes not treated with direct laser photocoagulation. The difference in recurrences was statistically significant (P = .02). Pigment changes indistinguishable from age-related macular degeneration frequently occurred in eyes with CSR. The difference in the development of such pigment changes between eyes with CSR (33 of 38) and nonaffected fellow eyes (12 of 35) was significant (P = .001). CONCLUSIONS: The decreased rate of CSR recurrence after direct laser photocoagulation reported in an earlier study was sustained with follow-up beyond 10 years. Pigmentary changes in the fundus indistinguishable from those associated with age-related macular degeneration developed in eyes affected with CSR, probably as a consequence of the presence of subretinal fluid accompanying the CSR rather than from early age-related macular degeneration. 39 AUTHOR Buhl M AUTHOR Liesenhoff O AUTHOR Kampik A TITLE [Pathogenesis and therapy of central serous retinopathy] SOURCE Ophthalmologe 1994 Dec;91(6):741-4 ABSTRACT There is no consensus in the literature on the etiology and therapy of central serous retinopathy. We conducted a retrospective study to find out whether patients treated with argon laser coagulation (ALK) experienced long-term visual acuity improvement. We were also concerned to find whether choroidal perfusion was involved in the etiology. PATIENTS: In all, 28 patients (4 women/24 men) with RCS confirmed by angiography were analyzed. All patients were followed up from 1988 to 1992. Patients with chronic recurrent RCS were not considered. Angiography was performed to examine the type and localization of the leakage and also the choroidal perfusion. Patients who were treated with ALK were compared with patients who were not. RESULTS: Only 9 patients were treated with carefully directed ALK. Their mean visual acuity was 0.5 (STD 0.09) before therapy. After treatment the mean visual acuity was improved to an average of 0.8 (0.23). The follow-up time was up to 56 weeks. The patients without ALK had an initial visual acuity of 0.6 (0.21) which improved to 0.8 (0.22) during an observation period of 60 weeks. By the end of the study the visual acuity was the same in both groups. In 46% of all patients delayed choroidal perfusion was seen on angiography. CONCLUSION: There was no difference in visual acuity between patients treated with and without ALK. The angiographic examinations suggest general changes in choroidal perfusion in patients with RCS.